BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38514361)

  • 1. Reliably making the primary diagnosis of mesothelioma utilizing serous fluid cytology specimens: an institutional experience.
    Jones TE; Geisler DL; Baskota SU; Ohori NP; Cuda J; Khader SN
    J Am Soc Cytopathol; 2024; 13(3):174-182. PubMed ID: 38514361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
    Hwang HC; Sheffield BS; Rodriguez S; Thompson K; Tse CH; Gown AM; Churg A
    Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
    Berg KB; Churg AM; Cheung S; Dacic S
    Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
    Chevrier M; Monaco SE; Jerome JA; Galateau-Salle F; Churg A; Dacic S
    Cancer Cytopathol; 2020 Dec; 128(12):939-947. PubMed ID: 32678499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology.
    Aydogdu G; Özekinci S
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10001-10007. PubMed ID: 37916370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of early pleural fluid samples in patients with mesothelioma: A case series exploration of morphology, BAP1, and CDKN2A status with implications for the concept of mesothelioma in situ in cytology.
    Louw A; van Vliet C; Peverall J; Colkers S; Acott N; Creaney J; Lee YCG; Chai SM
    Cancer Cytopathol; 2022 May; 130(5):352-362. PubMed ID: 35143119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology.
    Chen L; Caldero SG; Gmitro S; Smith ML; De Petris G; Zarka MA
    Cancer Cytopathol; 2014 Jan; 122(1):70-5. PubMed ID: 23983174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey.
    Paintal A; Raparia K; Zakowski MF; Nayar R
    Cancer Cytopathol; 2013 Dec; 121(12):703-7. PubMed ID: 24039177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
    Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Nabeshima K
    Pathol Int; 2020 Sep; 70(9):671-679. PubMed ID: 32542810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of BRCA1-associated protein 1 in the diagnosis of malignant mesothelioma in effusion and fine-needle aspiration cytology.
    Hatem L; McIntire PJ; He B; Gogineni S; Ho M; Mathew S; Margolskee EM; Siddiqui MT; Rao RA
    Diagn Cytopathol; 2019 Mar; 47(3):160-165. PubMed ID: 30520251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens.
    Althakfi W; Gazzo S; Blanchet M; Isaac S; Piaton E; Villeneuve L; Glehen O; Gilly FN; Brevet M
    Cytopathology; 2020 Jan; 31(1):5-11. PubMed ID: 31713897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma.
    Pillappa R; Maleszewski JJ; Sukov WR; Bedroske PP; Greipp PT; Boland JM; Yi ES; Peikert T; Aubry MC; Roden AC
    Am J Surg Pathol; 2018 Feb; 42(2):256-263. PubMed ID: 29076876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology.
    Andrici J; Sheen A; Sioson L; Wardell K; Clarkson A; Watson N; Ahadi MS; Farzin M; Toon CW; Gill AJ
    Mod Pathol; 2015 Oct; 28(10):1360-8. PubMed ID: 26226841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BAP1 Immunostain and CDKN2A (p16) FISH Analysis: Clinical Applicability for the Diagnosis of Malignant Mesothelioma in Effusions.
    Walts AE; Hiroshima K; McGregor SM; Wu D; Husain AN; Marchevsky AM
    Diagn Cytopathol; 2016 Jul; 44(7):599-606. PubMed ID: 27121152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
    Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
    Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions.
    Cozzi I; Oprescu FA; Rullo E; Ascoli V
    Diagn Cytopathol; 2018 Jan; 46(1):9-14. PubMed ID: 28994508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
    Kinoshita Y; Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Hiroshima K; Oda Y; Nabeshima K
    Cancer Cytopathol; 2018 Jan; 126(1):54-63. PubMed ID: 29053210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic mesothelioma biomarkers in effusion cytology.
    Eccher A; Girolami I; Lucenteforte E; Troncone G; Scarpa A; Pantanowitz L
    Cancer Cytopathol; 2021 Jul; 129(7):506-516. PubMed ID: 33465294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-hmC loss is another useful tool in addition to BAP1 and MTAP immunostains to distinguish diffuse malignant peritoneal mesothelioma from reactive mesothelial hyperplasia in peritoneal cytology cell-blocks and biopsies.
    Alsugair Z; Kepenekian V; Fenouil T; Glehen O; Villeneuve L; Isaac S; Hommell-Fontaine J; Benzerdjeb N
    Virchows Arch; 2022 Jul; 481(1):23-29. PubMed ID: 35575935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of MTAP and BAP1 staining loss and P16/CDKN2A deletion in pleural cytology specimens and its role in the diagnosis of mesothelioma.
    Şeker NS; Tekin E; Ak G; Metintaş M; Metintaş S; Dündar E
    Diagn Cytopathol; 2024 Apr; 52(4):211-216. PubMed ID: 38243885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.